Thursday 1 November 2018

PART LXI: INJECTION #5

THURSDAY, NOVEMBER 1, 2018


Nov. 1, 2018
We're on to appointment #61. Happily, it has all changed. For this, and the next appointment, hubby only needs go to our GP's office for his needle.

We are aware of health issues, which are really side effects of this chemical-induced menopause. I would bet that this result is more a factor of weight gain, the change in metabolism, bone density loss, and the mild depression from the hormone changes.

Hubby is exercising, lost 10 lbs. prior to treatment, is going to a naturopath for calcium supplements, to combat the bone density loss.

Antihormone Therapy Linked with Higher Heart Failure Risk in Prostate Cancer Patients
Androgen deprivation therapy was associated with a 72 percent higher risk of heart failure in a study of patients with prostate cancer. 
In The Journal of Clinical Pharmacology study, incidence rates of heart failure per 100 person-years within a 1-year follow-up period were 4.00 and 1.89 for androgen deprivation therapy users and nonusers, respectively. (A person-year is the number of years of follow-up multiplied by the number of people in the study.) The study included data from the Taiwan Longitudinal Health Insurance Database 2005 on 1244 patient who received androgen deprivation therapy and 1806 patients who did not.
 “The results of our study provide information for prostate cancer patients to be aware of the potential heart failure risk of receiving androgen deprivation therapy,” the authors wrote. “We recommend that clinicians should counsel their patients regarding modifiable heart failure risk factors, suggest they improve their lifestyle, and further provide relevant cardiovascular examination for prostate cancer patients receiving androgen deprivation therapy.”

No comments: